BlackRock, Inc. 13D and 13G filings for KalVista Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-29 3:26 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
BlackRock Inc. BLK |
2,242,025 6.500% |
669,604 (+42.58%) |
Filing |
| 2023-01-06 1:46 pm Purchase |
2022-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
BlackRock Inc. BLK |
1,572,421 4.600% |
67,801 (+4.51%) |
Filing |
| 2022-01-31 5:49 pm Purchase |
2021-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
BlackRock Inc. BLK |
1,504,620 6.100% |
391,240 (+35.14%) |
Filing |
| 2021-02-02 2:56 pm Purchase |
2020-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
BlackRock Inc. BLK |
1,113,380 6.200% |
1,113,380 (New Position) |
Filing |